GCP
MBRX icon

GSA Capital Partners’s Moleculin Biotech MBRX Stock Holding History

GSA Capital Partners’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-83
Closed -$114K – 1636
2021
Q2 		$114K Buy
+83
New +$113K 0.01% 1241

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
OQS
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

GSA Capital Partners's MBRX Position: Q3 2021 in Review

GSA Capital Partners sold out of Moleculin Biotech (MBRX) in Q3 2021, closing a stake of 83 shares — an estimated $114K sold.

GSA Capital Partners first reported a position in MBRX in Q2 2021 and held it in 1 quarter. The position peaked at $114K in Q2 2021. 21 funds tracked by Wall St. Rank hold MBRX as of Q3 2021.

  • GSA Capital Partners reported no remaining Moleculin Biotech position as of Q3 2021 after selling out during the quarter.
  • GSA Capital Partners sold 83 Moleculin Biotech shares in Q3 2021, an estimated $114K.
  • GSA Capital Partners first reported a position in Moleculin Biotech in Q2 2021 and held it in 1 quarter.
  • GSA Capital Partners's Moleculin Biotech position peaked at $114K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2021.

Based on GSA Capital Partners's 13F filing for Q3 2021, filed 12 Nov 2021.